AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A dermal application system, which is a self-adhesive matrix system, consisting of aminolaevulinic acid (ALA) derivative crystals suspended in a polymer matrix, wherein the polymer matrix consists of polymers from the group consisting of acrylates, silicon polymers, and polyisobutylene, wherein the ALA derivative is an aminolaevulinic acid salt or an aminolaevulinic acid ester or a salt thereof, wherein a substantial amount of the crystals of the ALA derivative have a mean diameter of 20 μm to 200 μm, wherein the ALA ester is a compound of the general formula



,

wherein R1 is an unsubstituted alkyl group, and each of R2 independently from one another represents a hydrogen atom or an unsubstituted alkyl group.

2. (Previously Presented) Application system according to claim 1, characterised in that the polymer matrix is water-permeable.

3. (Canceled)

4. (Previously Presented) Application system according to claim 1, characterised in that a substantial amount of the crystals of the ALA derivative have a mean diameter of 30 μm to 190 μm.

5. (Previously Presented) Application system according to claim 4, characterised in that a substantial amount of the crystals of the ALA derivative have a mean diameter of 90 μm to 160 μm.

6. (Previously Presented) Application system according to claim 1, characterised in that the aminolaevulinic acid derivative is present in a concentration of 1 to 50 wt. % relative to the polymer matrix.

7-8. (Canceled)

9. (Previously Presented) Application system according to claim 1, characterised in that it releases at least 30% of the ALA derivative within 30 minutes.

10-12. (Canceled)

13. (Currently Amended) Application system according to claim 1 ~~claim 10~~, characterised in that the alkyl group has 1 to 10 carbon atoms.

14. (Currently Amended) A dermal application system, which is a self-adhesive matrix system, consisting of aminolaevulinic acid (ALA) derivative crystals suspended in a polymer matrix, wherein the ALA derivative is an aminolaevulinic acid salt or an aminolaevulinic acid ester or a salt thereof, wherein a substantial amount of the crystals of the ALA derivative have a mean diameter of 20 μm to 200 μm, wherein the ALA derivative is ~~5-amino levulinic~~ 5-amino-laevulinic acid methyl ester, ~~5-amino levulinic~~ 5-amino-laevulinic acid ethyl ester, ~~5-amino~~

~~levulinic~~ 5-amino-laevulinic acid propyl ester, ~~5-amino levulinic~~ 5-amino-laevulinic acid butyl ester, ~~5-amino levulinic~~ 5-amino-laevulinic acid pentyl ester, ~~5-amino levulinic~~ 5-amino-laevulinic acid hexyl ester, ~~5-amino levulinic~~ 5-amino-laevulinic acid heptyl ester, ~~5-amino levulinic~~ 5-amino-laevulinic acid octyl ester, or a pharmaceutically acceptable salt thereof.

15-22. (Canceled)